Literature DB >> 25265876

Combinations of various CpG motifs cloned into plasmid backbone modulate and enhance protective immunity of viral replicon DNA anthrax vaccines.

Yun-Zhou Yu1, Yao Ma, Wen-Hui Xu, Shuang Wang, Zhi-Wei Sun.   

Abstract

DNA vaccines are generally weak stimulators of the immune system. Fortunately, their efficacy can be improved using a viral replicon vector or by the addition of immunostimulatory CpG motifs, although the design of these engineered DNA vectors requires optimization. Our results clearly suggest that multiple copies of three types of CpG motifs or combinations of various types of CpG motifs cloned into a viral replicon vector backbone with strong immunostimulatory activities on human PBMC are efficient adjuvants for these DNA vaccines to modulate and enhance protective immunity against anthrax, although modifications with these different CpG forms in vivo elicited inconsistent immune response profiles. Modification with more copies of CpG motifs elicited more potent adjuvant effects leading to the generation of enhanced immunity, which indicated a CpG motif dose-dependent enhancement of antigen-specific immune responses. Notably, the enhanced and/or synchronous adjuvant effects were observed in modification with combinations of two different types of CpG motifs, which provides not only a contribution to the knowledge base on the adjuvant activities of CpG motifs combinations but also implications for the rational design of optimal DNA vaccines with combinations of CpG motifs as "built-in" adjuvants. We describe an efficient strategy to design and optimize DNA vaccines by the addition of combined immunostimulatory CpG motifs in a viral replicon DNA plasmid to produce strong immune responses, which indicates that the CpG-modified viral replicon DNA plasmid may be desirable for use as vector of DNA vaccines.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25265876     DOI: 10.1007/s00430-014-0359-9

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  35 in total

Review 1.  CpG motifs for optimization of DNA vaccines.

Authors:  H L Davis
Journal:  Dev Biol (Basel)       Date:  2000

2.  Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine.

Authors:  Maria L Knudsen; Alice Mbewe-Mvula; Maximillian Rosario; Daniel X Johansson; Maria Kakoulidou; Anne Bridgeman; Arturo Reyes-Sandoval; Alfredo Nicosia; Karl Ljungberg; Tomás Hanke; Peter Liljeström
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors.

Authors:  Cevayir Coban; Ken J Ishii; Mayda Gursel; Dennis M Klinman; Nirbhay Kumar
Journal:  J Leukoc Biol       Date:  2005-06-16       Impact factor: 4.962

4.  Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs.

Authors:  A M Krieg; T Wu; R Weeratna; S M Efler; L Love-Homan; L Yang; A K Yi; D Short; H L Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

Review 5.  DNA vaccines: an historical perspective and view to the future.

Authors:  Margaret A Liu
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

6.  Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.

Authors:  Dianna Rynkiewicz; Melinda Rathkopf; Iain Sim; A Thomas Waytes; Robert J Hopkins; Lallan Giri; Deborah DeMuria; Janet Ransom; James Quinn; Gary S Nabors; Carl J Nielsen
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

7.  Immunostimulatory DNA sequences necessary for effective intradermal gene immunization.

Authors:  Y Sato; M Roman; H Tighe; D Lee; M Corr; M D Nguyen; G J Silverman; M Lotz; D A Carson; E Raz
Journal:  Science       Date:  1996-07-19       Impact factor: 47.728

8.  Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine.

Authors:  Yoshitsugu Kojima; Ke-Qin Xin; Takaaki Ooki; Kenji Hamajima; Tomohiro Oikawa; Kaori Shinoda; Tomomi Ozaki; Yuka Hoshino; Nao Jounai; Masatoshi Nakazawa; Dennis Klinman; Kenji Okuda
Journal:  Vaccine       Date:  2002-07-26       Impact factor: 3.641

9.  CpG motifs are efficient adjuvants for DNA cancer vaccines.

Authors:  Achim Schneeberger; Christine Wagner; Anja Zemann; Petra Lührs; Raphaela Kutil; Manfred Goos; Georg Stingl; Stephan N Wagner
Journal:  J Invest Dermatol       Date:  2004-08       Impact factor: 8.551

10.  Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine.

Authors:  Karl Ljungberg; Alan C Whitmore; Meagan E Fluet; Timothy P Moran; Reed S Shabman; Martha L Collier; Annette A Kraus; Joseph M Thompson; David C Montefiori; Clayton Beard; Robert E Johnston
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

View more
  5 in total

1.  Increased humoral immunity by DNA vaccination using an α-tocopherol-based adjuvant.

Authors:  Ingrid Karlsson; Marie Borggren; Jens Nielsen; Dennis Christensen; Jim Williams; Anders Fomsgaard
Journal:  Hum Vaccin Immunother       Date:  2017-06-14       Impact factor: 3.452

Review 2.  Molecular mechanisms for enhanced DNA vaccine immunogenicity.

Authors:  Lei Li; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2015-12-28       Impact factor: 5.217

Review 3.  Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses.

Authors:  Andri Vasou; Nazife Sultanoglu; Stephen Goodbourn; Richard E Randall; Leondios G Kostrikis
Journal:  Viruses       Date:  2017-07-13       Impact factor: 5.048

Review 4.  Engineering DNA vaccines against infectious diseases.

Authors:  Jihui Lee; Shreedevi Arun Kumar; Yong Yu Jhan; Corey J Bishop
Journal:  Acta Biomater       Date:  2018-08-31       Impact factor: 8.947

Review 5.  Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines.

Authors:  Saed Abbasi; Satoshi Uchida
Journal:  Pharmaceutics       Date:  2021-05-01       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.